Anaptysbio (ANAB) Gains from Investment Securities (2016 - 2017)
Anaptysbio's (ANAB) quarterly Gains from Investment Securities came in at $1.4 million in Q1 2017, up 460.42% YoY from $243744.8 in Q1 2016, and up 25.21% on a QoQ basis from $1.1 million in Q4 2016.
Powered by 
Analysis
Anaptysbio (ANAB) Gains from Investment Securities (2016 - 2017) Analysis & Trends
Anaptysbio (ANAB) has 2 years of Gains from Investment Securities data on file, last reported at $1.4 million in Q1 2017.
- Quarterly Gains from Investment Securities rose 460.42% year-over-year to $1.4 million in Q1 2017, while the trailing twelve-month figure through Dec 2017 was $1.4 million (up 80.69% YoY) and the FY2017 annual result came in at $1.4 million, up 80.69% from the prior year.
- Gains from Investment Securities rose to $1.4 million in Q1 2017, from $1.1 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $1.4 million in Q1 2017 to a low of -$379000.0 in Q1 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Anaptysbio | 1.62 Bn | 1.33 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2017 | 1.37 Mn |
| Dec 31, 2016 | 1.09 Mn |
| Sep 30, 2016 | 47,000.00 |
| Jun 30, 2016 | -3,000.00 |
| Mar 31, 2016 | -379,000.00 |